Drug Designing: Open Access
Open Access

Small tri-peptide plays a leading role in promote bone marrow stem cell differentiation into isletlike insulin positive cells

International Conference and Expo on Drug Discovery & Designing

August 11-13, 2015 Frankfurt, Germany

Luguang Luo, Zhengke Wang, Fang Xiong and John Z Luo

Posters-Accepted Abstracts: Drug Des

Abstract :

Destruction of islet β-cell results in hyperglycemia in diabetes. Replacement of β-cell may offer a long term solution. Adult bone
marrow stem cells (BMSC) may be programmed with specific factors to induce differentiation. Histone deacetylase (HDAC)
inhibitor trichostatin A (TSA) and differentiation agent (-)-indolactam V (ILV) has been reported to convert human BMSC
into functional β-cell. In addition, Thyrotropin Release Hormone (TRH), a Neuropeptide, has been implicated to initiate β-cell
differentiation in the embryonic pancreas. We hypothesize that a cocktail containing HDAC, TSA, ILV, and TRH has the ability to
induce BMSC into functioning insulin producing cells. In this presentation, we will briefly introduce biological effects of TRH and
utilizing RIP-Cre cellular labeling technology along with stem cell biology to test TRH and TSA convert BMSC cells into insulin
positive cells in vitro. Reprogramming BMSC into insulin positive cells with a cocktail of small molecules creates a new protocol for
generating human insulin positive cells. However, future studies on the control of differentiation and possible teratoma formation
needs to be performed to assess safety clinically.